National Bank of Canada
MLTX icon

National Bank of Canada’s MoonLake Immunotherapeutics MLTX Stock Holding History

National Bank of Canada’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2
Closed -$108 – 3040
2024
Q4 		$108 Buy
+2
New +$102 ﹤0.01% 2794

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

National Bank of Canada's MLTX Position: Q1 2025 in Review

National Bank of Canada sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2025, closing a stake of 2 shares — an estimated $108 sold.

National Bank of Canada first reported a position in MLTX in Q4 2024 and held it in 1 quarter. The position peaked at $108 in Q4 2024. 136 funds tracked by Wall St. Rank hold MLTX as of Q1 2025.

  • National Bank of Canada reported no remaining MoonLake Immunotherapeutics position as of Q1 2025 after selling out during the quarter.
  • National Bank of Canada sold 2 MoonLake Immunotherapeutics shares in Q1 2025, an estimated $108.
  • National Bank of Canada first reported a position in MoonLake Immunotherapeutics in Q4 2024 and held it in 1 quarter.
  • National Bank of Canada's MoonLake Immunotherapeutics position peaked at $108 in Q4 2024.
  • 136 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2025.

Based on National Bank of Canada's 13F filing for Q1 2025, filed 12 May 2025.